Andrew Tomlin's research while affiliated with University of Auckland and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (6)
Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother–child pairs data in Hong Kong, New Zealand, Taiwan, Fi...
Objectives
Opioid use has increased globally, dramatically increasing opioid overdose, dependence, abuse and mortality. Limited research is available on opioid use patterns in older adults in New Zealand and internationally. This study aims to address this gap by determining the incidence and prevalence of opioid use among older adults (age ≥65 yea...
Background
Long-term opioid use and associated adverse outcomes have increased dramatically in recent years. Limited research is available on long-term opioid use in older adults.
Objective
We aimed to determine the incidence and predictors of long-term or persistent opioid use (POU) amongst opioid-naïve older adults without a cancer diagnosis.
M...
Introduction:
Asthma is one of the most common long-term conditions in the world, with New Zealand (NZ) having one of the highest rates of asthma symptoms. Despite the significant burden of asthma in NZ, there is a lack of data on asthma exacerbation rates in NZ and how these have varied over time. This study is a national population-based study o...
Background
New Zealand (NZ) implemented some of the strictest restrictions during the novel coronavirus pandemic (coronavirus disease 2019 [COVID-19]), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How this impacted asthma exacerbation rates in NZ is unknown.
Objective
We sought to explore the effects of the COVID-19 rest...
Unique aspects of New Zealand’s (NZ) health system allow for a novel pharmacoepidemiologic approach to conducting population-based clinical research. A defined cohort of surgical and trauma patients would facilitate future studies into opioid utilisation, outcomes, and other questions related to surgery and trauma. We aimed to describe all patients...
Citations
... In NovelSTART there was a 51% lower rate of exacerbations in the ICS/FF as-needed group than in the SABA as-needed group [6], and in SYGMA-1, there was a 64% reduction in the rate of severe exacerbations in the ICS/FF as-needed group compared with the SABA asneeded group [7]. The PRIME population demonstrated a lower likelihood of exacerbations than either the NovelSTART or SYGMA-1 populations, potentially as a consequence of COVID-19 social distancing and 'lockdown' measures reducing the incidence of virusinduced acute asthma during the period of the study [13,14]. In addition, it is possible that the PRIME population had less severe asthma than the other studiesfor example, whereas 6 patients (0.7% overall) in PRIME had a severe exacerbation in the year prior to entry (all in the ICS/FF as-needed group), this was the case for 7.3% and 19.7% patients in NovelSTART and SYGMA-1, respectively [6,7]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/647227743670272-1531322527418_Q64/Amy-Chan-12.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/981214282399745-1610951123211_Q64/Kebede-Beyene.jpg)
... 23 This is a conservative estimate with our recent work finding that asthma attack rates have increased significantly in the last 10 years with the most recent data showing a 25% attack rate with an average of 1.7 attacks per patient per year. 24 Based on the events per variable method, the ratio of the number of individuals with the outcome event to the number of candidate predictors should ideally be 10 individuals per a candidate risk factor for the outcome event. 25 26 With our sample size, there is a risk of overfitting as there may not be sufficient events for the number of variables we wish to include in the model. ...
